Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

• Market Cap: ₹12.38B
• Dividend Yield: 1.24%
• Average Volume (3M): 3.85K
• Price to Earnings (P/E): 28.8
• Beta (1Y): 1.07
• Revenue Growth: 24.60%
• EPS Growth: 153.56%
• Country: IN
• Employees: 1,025
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.64
• Shares Outstanding: 66,890,450
• 10 Day Avg. Volume: 3,534
• 30 Day Avg. Volume: 3,854
• PEG Ratio: 0.18
• Price to Book (P/B): 6.09
• Price to Sales (P/S): 5.44
• P/FCF Ratio: 26.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ₹201.00 ▲(3.88% Upside)
• Action: Reiterated Date: 10/25/25
• Date: Action: Reiterated 10/25/25

Jagsonpal Pharmaceuticals Ltd. shows strong financial health with consistent growth and profitability, which is the most significant factor in its stock score. However, technical indicators reflect a bearish trend, and the valuation is moderate with limited dividend appeal. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue growth & margins

Sustained revenue expansion with healthy gross and net margins indicates durable demand for branded formulations and efficient cost control. That combination supports predictable operating earnings, capacity to reinvest in the business, and resilience to cyclical pressure over the next 2–6 months.

Low leverage / strong equity base

A high equity ratio and low debt levels materially reduce financial risk and interest burden, giving the company flexibility to fund working capital, targeted capex or opportunistic investments without stressing liquidity. This structural strength supports stability across business cycles.

Cash conversion capability

Strong conversion of earnings into operating cash flow underpins sustainable cash generation ability, enabling dividend payments, organic reinvestment and reduced reliance on external financing. Reliable OCF conversion is a durable metric of underlying business health.

Negative Factors

Declining cash reserves

A falling cash and short-term investment balance weakens near-term liquidity buffers. If working capital needs or unexpected expenditures rise, the company may need to access external funding or curtail discretionary investment, constraining operational flexibility over the medium term.

Earnings per share decline

A substantial negative EPS growth rate suggests lower earnings power per share year-over-year, which can reflect margin pressure, one-offs, or dilution. Persistent EPS decline erodes shareholder returns and can limit reinvestment or dividend capacity if not reversed.

Free cash flow variability

Variable free cash flow growth reduces predictability of available cash for capex, acquisitions, or shareholder returns. Even with strong OCF, inconsistent FCF introduces execution risk for strategic plans and raises reliance on balance sheet buffers during weaker periods.

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.

How the Company Makes Money

Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated when the company markets its branded products to prescribers (e.g., doctors) and fulfills demand through distributors/stockists, wholesalers, hospitals/clinics, and retail pharmacies; collections flow back through the pharma trade channel to the company. Key revenue streams typically include (a) domestic branded formulation sales across its therapeutic portfolio and (b) institutional/tender or bulk supplies where applicable; however, a public, product-wise split of revenue streams is null. The company’s earnings are influenced by prescription demand for its brands, the breadth and effectiveness of its sales and distribution network, pricing and product mix, manufacturing and sourcing costs, and compliance with Indian pharmaceutical regulations. Specific long-term partnerships, licensing arrangements, or material export/contract-manufacturing revenue contributions are null due to insufficient publicly available detail in this response.

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Jagsonpal Pharmaceuticals Ltd. exhibits strong financial performance with robust revenue growth, healthy profit margins, and a solid balance sheet. The company demonstrates efficient cost management and operational efficiency, although there is some concern regarding liquidity due to declining cash reserves.

Income Statement

Jagsonpal Pharmaceuticals Ltd. has demonstrated strong revenue growth over the years, with a notable increase in net income as well. Gross profit margin and net profit margin are healthy, indicating efficient cost management and profitability. The increase in EBIT and EBITDA margins further underscores the company's operational efficiency. Overall, the income statement reflects a robust and growing financial performance.

Balance Sheet

The company's balance sheet is solid, characterized by a strong equity base and a low debt-to-equity ratio, indicating low leverage and financial stability. The equity ratio is high, showcasing a strong asset base funded by equity rather than debt. This structure mitigates financial risk and provides a foundation for sustainable growth. However, the decline in cash and short-term investments over time could be a point of concern for liquidity management.

Cash Flow

Cash flow analysis shows a positive trajectory in operating cash flow and free cash flow, which supports the company's capacity to reinvest and pay dividends. The operating cash flow to net income ratio is strong, highlighting effective conversion of earnings into cash. However, the free cash flow growth rate has shown some variability, which could indicate fluctuations in capital expenditures or cash management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.83B	2.69B	2.09B	2.37B	2.18B	1.88B
Gross Profit	1.80B	1.72B	652.59M	1.44B	1.28B	1.07B
EBITDA	862.81M	510.71M	323.46M	363.96M	284.53M	234.72M
Net Income	619.42M	553.61M	224.63M	267.21M	188.55M	170.58M
Balance Sheet
Total Assets	2.99B	2.78B	2.17B	1.95B	1.68B	1.64B
Cash, Cash Equivalents and Short-Term Investments	1.59B	1.29B	1.48B	1.15B	472.77M	618.82M
Total Debt	88.36M	92.39M	89.41M	60.01M	52.47M	67.88M
Total Liabilities	461.88M	383.10M	296.76M	360.56M	375.99M	422.73M
Stockholders Equity	2.53B	2.40B	1.87B	1.59B	1.31B	1.22B
Cash Flow
Free Cash Flow	245.77M	549.52M	349.18M	463.37M	51.31M	277.53M
Operating Cash Flow	246.75M	553.00M	351.66M	466.54M	55.98M	282.22M
Investing Cash Flow	-82.07M	-451.47M	-245.48M	-576.71M	-257.79M	-22.64M
Financing Cash Flow	-148.90M	-116.98M	-89.11M	-4.57M	-175.52M	-68.28M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 193.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Positive. The current price of 193.5 is above the 20-day moving average (MA) of 175.02, above the 50-day MA of 175.68, and below the 200-day MA of 214.49, indicating a neutral trend. The MACD of 2.06 indicates Negative momentum. The RSI at 58.63 is Neutral, neither overbought nor oversold. The STOCH value of 58.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LINCOLN	78 Outperform	₹11.99B	8.47	―	0.37%	―	―
BLISSGVS	74 Outperform	₹22.83B	18.57	―	0.28%	7.51%	71.81%
JAGSNPHARM	67 Neutral	₹12.38B	28.83	―	1.24%	24.60%	153.56%
THEMISMED	62 Neutral	₹7.14B	22.95	―	0.48%	-18.86%	-150.92%
HESTERBIO	61 Neutral	₹11.95B	38.81	―	0.44%	-3.84%	86.82%
BAJAJHCARE	53 Neutral	₹9.76B	20.91	―	0.24%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Jagsonpal Pharmaceuticals Ltd. Corporate Events

Jagsonpal Pharma Discloses Rs 4.82 Crore Tax Demand, Plans Appeal

Jagsonpal Pharmaceuticals Ltd. has disclosed that it received an income-tax assessment order for assessment year 2024-25 from the Income Tax Department’s Faceless Assessment Unit, leading to a tax demand of Rs. 4.82 crore arising from disallowance of certain expenses claimed in its return. The company plans to appeal the order within the prescribed timelines and, while acknowledging the potential for penalties, maintains that it has strong grounds in the case and does not expect any material financial or operational impact from the demand at this stage.

The disclosure underscores Jagsonpal’s effort to keep markets informed about pending tax litigation that could affect perceptions of its compliance posture, even though no penalties or restrictions have yet been imposed. For stakeholders, the company’s view that the demand is unlikely to be material provides some reassurance, but the matter remains contingent on the outcome of the appellate process, which could influence future tax outflows and the resolution of similar expense-related disputes.

Jagsonpal Pharma Grants 1.15 Million Stock Options Under ESOP 2022

Jagsonpal Pharmaceuticals Ltd. has approved the grant of 1,152,500 employee stock options under its 2022 Employee Stock Option Plan at an exercise price of Rs 139 per option, each convertible into equity shares of Rs 2. The options will vest in four equal annual tranches starting from the first anniversary of the grant, aligning long-term incentives for eligible employees with shareholder value and the company’s growth trajectory.

The move underscores Jagsonpal’s use of equity-based compensation to retain and motivate key talent in a competitive pharmaceutical market, potentially improving employee alignment with the company’s performance and market capitalization over time. The structured vesting schedule is designed to support stability in the workforce and reinforce a long-term orientation among core staff and management.

Jagsonpal Pharmaceuticals Allots ESOP Shares, Ups Paid-Up Capital

Jagsonpal Pharmaceuticals has allotted 71,800 equity shares of Rs. 2 each to eligible employees under its Employee Stock Option Plan 2022, following the exercise of vested options. The newly issued shares, priced at an exercise rate of Rs. 94 with a premium of Rs. 92, rank pari passu with existing equity and carry the same rights as current shareholders.

With this allotment, the company’s paid-up share capital has increased from Rs. 13.37 crore to Rs. 13.39 crore, raising the total number of outstanding shares to 6,69,62,250. The move marginally dilutes existing holdings but underscores Jagsonpal’s use of stock-based compensation to incentivize and retain key employees, aligning their interests with long-term shareholder value.

Jagsonpal Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts

Jagsonpal Pharmaceuticals Ltd. has published newspaper advertisements in the English and Hindi editions of Business Standard containing extracts of its unaudited financial results for the quarter and nine-month period ended 31 December 2025, in compliance with Regulation 47 of SEBI’s Listing Obligations and Disclosure Requirements. By formally notifying the stock exchanges of this disclosure, the company is reinforcing its regulatory compliance and transparency obligations to investors and other stakeholders regarding its interim financial performance.

Jagsonpal Pharma Board Approves Unaudited Q3 and Nine-Month FY25 Results

Jagsonpal Pharmaceuticals Ltd. announced that its Board of Directors has approved the unaudited financial results for the quarter and nine-month period ended December 31, 2025. The results, which have undergone a limited review by the company’s statutory auditors in line with Indian Accounting Standards and SEBI’s listing regulations, mark a key disclosure for investors and regulators, reinforcing ongoing compliance with financial reporting norms and providing stakeholders with updated visibility on the company’s financial performance for the current fiscal year to date.